Klick Health Acquires Comms Consultancy Oxford PharmaGenesis
This marks Klick’s third acquisition since the start of 2025.
Fresh off winning a “Triple Crown” at the Cannes Lions Festival of Creativity—taking home the trophies for Healthcare Agency of the Year, Healthcare Network of the Year and Independent Agency of the Year – Health—Klick Health is keeping the momentum going with a new acquisition.
The Toronto-based agency has picked up Oxford PharmaGenesis, Klick announced Tuesday, bulking up its offerings with the U.K.-based communications consultancy’s expertise in medical affairs and market access, as well as its presence across Europe, North America and the Asia-Pacific region.
The buyout is the latest in a string of moves by Klick in recent years to expand both its physical footprint and its scientific and commercial expertise to better serve life sciences clients. After setting up several global offices in 2022, Klick last year acquired U.S.-based Peregrine Market Access and the Singapore operations of Ward6, a healthcare marketing agency with a focus on HCP marketing and medical comms.
Oxford PharmaGenesis arrives under the Klick umbrella with a trove of scientific expertise in oncology, rare disease and other therapeutic areas, plus real-world evidence and health economics and outcomes research capabilities.
The addition will bring 500 staffers in the U.K., U.S. and Australia to the Klick team and ups the agency’s tally of global offices to 12.
Leerom Segal, Klick’s co-founder and chairman, said in a statement that the acquisition will allow the agency to provide its life sciences clients with “a scientific-to-commercial offering that unlocks the true potential of their innovations,” connecting research and data, medical and access strategy and stakeholder engagement across the commercialization lifecycle.
Financial details of the deal weren’t disclosed.
solli’s Final Thoughts
Klick’s string of acquisitions reflects a broader trend of conglomeration across the pharma media and marketing landscape.
Brands are increasingly seeking out commercialization partners they can work with from start to finish, rather than piecing together a roster of single-subject experts. That results in more interconnected full-lifecycle plans, with pre-launch med comms feeding into market access and creative strategies, and each piece accounted for in a cohesive measurement framework.
The Oxford PharmaGenesis buy in particular demonstrates a heightened focus on scientific and medical expertise—a crucial factor not only in brands’ work to build trust and authority among increasingly leery clinicians and consumers, but also in the rapidly accelerating use of AI tools that prioritize expert sources.
